US OptionsDetailed Quotes

FATE250516C1500

Watchlist

0.05
0.000.00%

15min DelayClose May 7 14:02 ET

0.00High0.00Low

Fate Therapeutics Stock Discussion

Teddy123

Apr 14 20:18

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE

$Fate Therapeutics (FATE.US)$
Game-Changing FDA Status: Fate's Off-the-Shelf Lupus Treatment Speeds Toward Approval

Trytosaveabit

Apr 14 20:05

news

$Fate Therapeutics (FATE.US)$ Reuters· 3 mins ago
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (Rmat) Designation From FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (Sle)

Jaguar8

Apr 14 20:01

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
Monday, 14th April at 8:00 am
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
– RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study...